Porosome Therapeutics unveils breakthrough Alzheimer’s research

Porosome Therapeutics has made significant strides in Alzheimer’s research, achieving FDA validation for organoid studies and developing novel Tau-targeting therapies. Their approach, which aims to modify disease progression, utilizes healthy porosomes to restore neuronal function. CEO Guillermo Marmol emphasized the platform's focus on core biological dysfunctions rather than just symptom management. The company is exploring FDA’s accelerated approval pathway due to promising results in reducing Tau protein levels and reversing Alzheimer’s pathology in human brain organoids. They are also leveraging AI to create peptides that neutralize toxic beta amyloid, enhancing neuronal activity.